TP53 and pancreatic adenocarcinoma: Although these align with our previous findings of cell cycle progression and failed TP53-mediated CDK control in MUC16-expressing cells, it is unclear why MUC16 is overexpressed in TP53 mutants of TCGA-PAAD cohort, including gain-of-function mutants (Figure 4B).